Learn more about whether Alvotech or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Learn more about whether Alvotech or Vericel Corporation is a better investment based on AAII's A+ Investor grades, which ...

Eylea’s sales in the United States declined ... The European Commission (EC) approved Dupixent to treat eosinophilic esophagitis in children aged 1 to 11 years, in November 2024.

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

In children 12 years of age and older ... the patent litigation and other related proceedings relating to EYLEA® (aflibercept) Injection), the ultimate outcome of any such proceedings and ...

The investigational gene therapy has shown significant improvements in hearing for children with profound ... pressures on existing products like EYLEA. It is one of the worst-performing large ...

The corporation’s expansion was driven by important products like EYLEA, Libtayo ... time gain of $146.5 million from the sale of a Rare Pediatric Disease Priority Review Voucher.

Xolair is the only FDA-approved drug to reduce allergic reactions in children and adults with one ... ophthalmology drug Eylea. Positive data from additional studies bode well for the drug.